Skip to main content

CureVac, GSK to focus on Covid variant vaccines in $180M deal

Drug developers GlaxoSmithKline plc and CureVac NV have announced plans to work jointly on vaccines against emerging Covid-19 variants of the coronavirus. In addition, GSK will help manufacture up to 100 million doses of CureVac’s first-generation Covid-19 vaccine candidate.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.